Cargando…

Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial

BACKGROUND: Does an intervention designed to foster patient-centered communication and shared decision making among GPs and their patients with poorly controlled type 2 diabetes mellitus reduce the level of HbA1c. METHODS: The DEBATE trial is a cluster-randomized controlled trial conducted in German...

Descripción completa

Detalles Bibliográficos
Autores principales: Wollny, Anja, Altiner, Attila, Daubmann, Anne, Drewelow, Eva, Helbig, Christian, Löscher, Susanne, Pentzek, Michael, Santos, Sara, Wegscheider, Karl, Wilm, Stefan, Löffler, Christin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593484/
https://www.ncbi.nlm.nih.gov/pubmed/31238871
http://dx.doi.org/10.1186/s12875-019-0977-9
_version_ 1783430056635269120
author Wollny, Anja
Altiner, Attila
Daubmann, Anne
Drewelow, Eva
Helbig, Christian
Löscher, Susanne
Pentzek, Michael
Santos, Sara
Wegscheider, Karl
Wilm, Stefan
Löffler, Christin
author_facet Wollny, Anja
Altiner, Attila
Daubmann, Anne
Drewelow, Eva
Helbig, Christian
Löscher, Susanne
Pentzek, Michael
Santos, Sara
Wegscheider, Karl
Wilm, Stefan
Löffler, Christin
author_sort Wollny, Anja
collection PubMed
description BACKGROUND: Does an intervention designed to foster patient-centered communication and shared decision making among GPs and their patients with poorly controlled type 2 diabetes mellitus reduce the level of HbA1c. METHODS: The DEBATE trial is a cluster-randomized controlled trial conducted in German primary care and including patients with type 2 diabetes mellitus having an HbA1c level of 8.0% (64 mmol/mol) or above at the time of recruitment. Data was measured before intervention (baseline, T0), 6–8 months (T1), 12–14 months (T2), 18–20 months (T3), and 24–26 months (T4) after baseline. Main outcome measure is the level of HbA1c. RESULTS: In both, the intervention and the control group the decline of the HbA1c level from T0 to T4 was statistically significant (− 0.67% (95% CI: − 0.80,-0.54%; p < 0.0001) and − 0.64% (95% CI: − 0.78, − 0.51%; p < 0.0001), respectively). However, there was no statistically significant difference between both groups. CONCLUSIONS: Although the DEBATE trial was not able to confirm effectiveness of the intervention tested compared to care as usual, the results suggest that patients with poorly controlled type 2 diabetes are able to improve their blood glucose levels. This finding may encourage physicians to stay on task to regularly approach this cohort of patients. TRIAL REGISTRATION: The trial was registered at ISRCTN registry under the reference ISRCTN70713571. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12875-019-0977-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6593484
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65934842019-07-09 Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial Wollny, Anja Altiner, Attila Daubmann, Anne Drewelow, Eva Helbig, Christian Löscher, Susanne Pentzek, Michael Santos, Sara Wegscheider, Karl Wilm, Stefan Löffler, Christin BMC Fam Pract Research Article BACKGROUND: Does an intervention designed to foster patient-centered communication and shared decision making among GPs and their patients with poorly controlled type 2 diabetes mellitus reduce the level of HbA1c. METHODS: The DEBATE trial is a cluster-randomized controlled trial conducted in German primary care and including patients with type 2 diabetes mellitus having an HbA1c level of 8.0% (64 mmol/mol) or above at the time of recruitment. Data was measured before intervention (baseline, T0), 6–8 months (T1), 12–14 months (T2), 18–20 months (T3), and 24–26 months (T4) after baseline. Main outcome measure is the level of HbA1c. RESULTS: In both, the intervention and the control group the decline of the HbA1c level from T0 to T4 was statistically significant (− 0.67% (95% CI: − 0.80,-0.54%; p < 0.0001) and − 0.64% (95% CI: − 0.78, − 0.51%; p < 0.0001), respectively). However, there was no statistically significant difference between both groups. CONCLUSIONS: Although the DEBATE trial was not able to confirm effectiveness of the intervention tested compared to care as usual, the results suggest that patients with poorly controlled type 2 diabetes are able to improve their blood glucose levels. This finding may encourage physicians to stay on task to regularly approach this cohort of patients. TRIAL REGISTRATION: The trial was registered at ISRCTN registry under the reference ISRCTN70713571. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12875-019-0977-9) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-25 /pmc/articles/PMC6593484/ /pubmed/31238871 http://dx.doi.org/10.1186/s12875-019-0977-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wollny, Anja
Altiner, Attila
Daubmann, Anne
Drewelow, Eva
Helbig, Christian
Löscher, Susanne
Pentzek, Michael
Santos, Sara
Wegscheider, Karl
Wilm, Stefan
Löffler, Christin
Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial
title Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial
title_full Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial
title_fullStr Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial
title_full_unstemmed Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial
title_short Patient-centered communication and shared decision making to reduce HbA1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled DEBATE trial
title_sort patient-centered communication and shared decision making to reduce hba1c levels of patients with poorly controlled type 2 diabetes mellitus - results of the cluster-randomized controlled debate trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593484/
https://www.ncbi.nlm.nih.gov/pubmed/31238871
http://dx.doi.org/10.1186/s12875-019-0977-9
work_keys_str_mv AT wollnyanja patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT altinerattila patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT daubmannanne patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT dreweloweva patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT helbigchristian patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT loschersusanne patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT pentzekmichael patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT santossara patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT wegscheiderkarl patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT wilmstefan patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial
AT lofflerchristin patientcenteredcommunicationandshareddecisionmakingtoreducehba1clevelsofpatientswithpoorlycontrolledtype2diabetesmellitusresultsoftheclusterrandomizedcontrolleddebatetrial